Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers
-
Published:2018-06
Issue:6
Volume:73
Page:845-846
-
ISSN:0302-2838
-
Container-title:European Urology
-
language:en
-
Short-container-title:European Urology
Reference11 articles.
1. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naïve prostate aancer: a systematic review and network meta-analysis;Wallis;Eur Urol,2018
2. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial;Gravis;Eur Urol,2016
3. Chemohormonal therapy in metastatic hormonesensitive prostate cancer;Sweeney;N Engl J Med,2015
4. Addition of docetaxel, zoledronic acid, or both to firstline long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016
5. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献